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ABSTRACT. Objective. To summarize the work performed by the Outcome Measures in Rheumatology
(OMERACT) Ultrasound (US) Working Group on the validation of US as a potential outcome measure
in gout. 
Methods. Based on the lack of definitions, highlighted in a recent literature review on US as an
outcome tool in gout, a series of iterative exercises were carried out to obtain consensus-based defini-
tions on US elementary components in gout using a Delphi exercise and subsequently testing these
definitions in static images and in patients with proven gout. Cohen’s κ was used to test agreement,
and values of 0–0.20 were considered poor, 0.20–0.40 fair, 0.40–0.60 moderate, 0.60–0.80 good, and
0.80–1 excellent.
Results. With an agreement of > 80%, consensus-based definitions were obtained for the 4 elementary
lesions highlighted in the literature review: tophi, aggregates, erosions, and double contour (DC). In
static images interobserver reliability ranged from moderate to almost perfect, and similar results were
found for the intrareader reliability. In patients the intraobserver agreement was good for all lesions
except DC (moderate). The interobserver agreement was poor for aggregates and DC but moderate
for the other components.
Conclusion. These first steps in evaluating the validity of US as an outcome measure for gout show
that the reliability of the definitions ranged from moderate to excellent in static images and somewhat
lower in patients, indicating that a standardized scanning technique may be needed, before testing the
responsiveness of those definitions in a composite US score. (First Release September 1 2015; 
J Rheumatol 2015;42:2177–81; doi:10.3899/jrheum.141294)
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Gout is the most common inflammatory joint disease1,2 and
is caused by the formation and deposition of monosodium
urate (MSU) crystals in joints, and/or soft tissues. The
conventional way to diagnose gout is based on clinical history
and physical examination in combination with serum urate
levels — but the key element in the diagnostic process is still
joint or tophus aspiration and subsequent polarized micro-
scopy for demonstration of MSU crystals3. Uncontrolled
hyperuricemia has been associated with renal failure, and
cardiovascular disease, with subsequent increased morbidity
and mortality4,5, stressing the importance of early and
accurate diagnosis. This need, in combination with the devel-
opment of new therapeutic options, has focused attention on
new imaging modalities and their potential to improve
diagnosis and disease management, possibly rendering joint
puncture unnecessary. A recent systematic literature review,
as part of the 3e Initiative on Diagnosis and Management of
Gout, highlighted dual energy computerized tomography
(DECT) and ultrasound (US) as promising imaging tools that
have shown markedly better performance than clinical
findings, although further testing is warranted6. In compari-
son to DECT, US appears to be more feasible because it is
patient-friendly, safe and non-invasive, free of ionizing
radiation, allows multiple target assessment in real time, and
may aid the aspiration process for relevant material for
microscopy7. Several published studies have highlighted the
ability of US to detect crystal deposits and have addressed its
possible role in very early diagnosis, based on their US
findings indicative of gout in patients with asymptomatic
hyperuricemia7,8,9. 
It is therefore critical to evaluate the US definitions
proposed for gout, and their reliability; and to pinpoint areas
in which further research is needed before US may be
considered a potential imaging technique in this area.
The Outcome Measures in Rheumatology (OMERACT)
US Working Group (Appendix 1) developed a gout subgroup
with the purpose of validating US as an imaging tool for gout.
If this objective is achieved, US may be implemented as an
outcome measure in gout. 
Is Ultrasound a Validated Outcome Measure in Gout?
In 2013, a systematic literature review was published evalu-
ating US as an outcome tool in gout and asymptomatic hyper-
uricemia10. The report found 18 out of 67 articles published
since 1975 to be eligible for review. Described in the literature
were 4 main pathologies related solely to gout: tophi, double
contour sign (DC), soft tissue abnormalities, and bony lesions.
The review highlighted that US was able to detect tophi
using magnetic resonance imaging (MRI) as a gold standard,
and this measure was found sensitive to change. The DC is
an articular cartilage abnormality related to the deposition of
crystals on the surface of the hyaline cartilage, which seemed
specific to gout, with excellent inter-reader reliability and
sensitive to change (the latter only in a very small patient
population). Soft tissue pathology such as intrasynovial
hyperechogenicity may be indicative of gout. US was less
sensitive than MRI for diagnosing erosions (bony lesions)
but more sensitive than conventional radiography, as is also
known from rheumatoid arthritis studies11,12.
Criterion and construct validity were assessed only for
tophi, and overall there was a lack of consensus on the defini-
tions of the 4 elementary lesions and their validity according
to the OMERACT filter13. 
Current Limitations of US in Gout Assessment 
Despite clear interest in this imaging technique for the
management of gout, the literature review clearly pointed to
a lack of clear US definitions for the main 4 elementary
lesions identified: tophi, DC, soft tissue hyperechogenicity
(punctuate crystal aggregates), and bony lesions (erosions).
This lack of consensus-based definitions impairs the ability
to validate US according to the OMERACT filter and
hampers widespread use of US in therapeutic clinical trials,
due to the difficulty to measure the same phenomenon.
In order to implement US in the management of patients
with established or suspected gout the “gout subgroup of the
OMERACT US Working Group” initiated a validation
process. The first step was to obtain consensus-based defini-
tions for the US elementary lesion as indicated by the liter-
ature review. This was accomplished by performing a Delphi
exercise14. Thirty-five rheumatologists performing US and
with an interest in gout were invited to participate, and 32
responded positively. After 3 Delphi rounds, > 80% agreement
was obtained for each definition (Figure 1), as follows:
Double contour. “Abnormal hyperechoic band over the
superficial margin of the articular hyaline cartilage,
independent of the angle of insonation and which may be
either irregular or regular, continuous, or intermittent and can
be distinguished from the cartilage interface sign.”
Tophus [independent of location (e.g. extraarticular/intra-
articular/intratendinous)]. “A circumscribed, inhomo-
geneous, hyperechoic and/or hypoechoic aggregation (which
may or may not generate posterior acoustic shadow), which
may be surrounded by a small anechoic rim.”
Aggregates [independent of location (intraarticular/intra-
tendinous)]. “Heterogeneous hyperechoic foci that maintain
their high degree of reflectivity even when the gain setting is
minimized or the insonation angle is changed, and which
occasionally may generate posterior acoustic shadow.”
Erosions. “An intra- and/or extraarticular discontinuity of the
bone surface (visible in 2 perpendicular planes).”
Agreement was obtained to use the existing definitions for
both synovitis and tenosynovitis15 because these may be
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co-components in gout disease. Agreement could not be
obtained to include synovitis (including Doppler activity) as
an elementary lesion indicative of gout, because the presence
of synovitis alone was not considered specific enough to
define gout disease because it is a key component in other
inflammatory arthropathies as well14. On the other hand, even
if erosions may also be seen in other arthropathy conditions,
since they may also be found extraarticularly in gout and may
possibly have a slightly different appearance, it was decided
to test, as part of the Delphi exercise, whether the existing
definition worked also in gout. Perfect agreement was
obtained to keep the definition close to the definition used
for erosions in general.
The second step was to test the reliability of the obtained
definitions in a Web exercise consisting of static images of
the elementary lesions. The Web exercise included 110 US
images of the 4 lesions obtained from feet and knees and 20
of these images were shown twice in order to test both inter-
and intrareader reliability. Twenty-seven of the 35 rheuma-
tologists participating in the Delphi exercise participated in
the reliability study. Cohen’s κ was used to evaluate inter-
and intrareader reliability. Κ values 0–0.20 were considered
poor; 0.20–0.40 fair; 0.40–0.60 moderate; 0.60–0.80 good;
and 0.80–1 excellent16. The unweighted κ values for all 4
lesions when reading the static images ranged from moderate
to almost perfect for interobserver reliability (0.54–0.98), and
similar results were found for the intrareader reliability
(0.65–0.93). The US lesion with a higher level of reliability
among the participants was the DC (intrareader: 0.98 and
inter-reader: 0.93) whereas the lowest level of agreement 
was seen for the soft tissue aggregates (intrareader: 0.54 and
inter-reader: 0.65)14.
The third step was to test the agreement and reliability of
the elementary lesions in a cohort of patients with gout.
Sixteen of the rheumatologists previously involved in the first
and second step participated in a workshop with 8 patients
with crystal-proven gout. Both intra- and inter-reader relia-
bility was assessed by scanning the patients twice within the
same day. The areas of attention were the intercondylar
region of the knee, the 1st metatarsophalangeal (MTP) joint,
and the patellar tendon.
Cohen’s κ was used to evaluate inter- and intrareader relia-
bility. Κ values of 0–0.20 were considered poor; 0.20–0.40
fair; 0.40–0.60 moderate; 0.60–0.80 good; and 0.80–1
excellent16. The results showed that the intraobserver
agreement was good for all lesions (0.61–0.73) except DC,
which was found to be only moderate (0.53). The inter-
observer agreement was surprisingly poor for aggregates and
DC (0.21 and 0.47, respectively) but moderate for the other
components (tophus 0.69 and erosions 0.74)17. “Aggregates”
was the lesion with the lowest reliability in the static image
exercise14 but even lower when assessed in patients,
especially between observers, raising the issue as to whether
or not the definition covers the US lesions it is supposed to
2179Terslev, et al: Validating ultrasound in gout
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Figure 1. Ultrasound images assessed in the Delphi exercise to evaluate proposed definitions of elementary lesions. A. Bold white arrows: tophus. B. Narrow
white arrows: aggregates. C. Open arrows: double contour. D. Asterisks: ultrasound examples of elementary lesions evaluated in the Delphi exercise. 
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describe (soft tissue hyperechogenicity believed to be
punctuate crystal deposits). Because a tophus is also a
collection of crystals, there may be overlap that impairs
agreement between observers. The US definition for “aggre-
gates” must be improved before it may be considered a US
elementary lesion in gout. 
At this point in the validation process no attempt was
made to define which components define acute gout and
which define chronic gout; nor was any attempt made to
define a core set of components to constitute a scoring
system.
Future Steps
Tophus burden is proposed as part of the clinical core domain
in chronic gout, and joint inflammation and joint damage
imaging are proposed as a discretionary domain. Joint
swelling and joint tenderness are proposed as part of the
clinical core domain for acute gout18. For both chronic and
acute gout the suggested parameters in the core domain set
may be evaluated by US. The first steps, namely, to validate
further use of US in gout have been taken. The elementary US
components in gout that have been identified by the literature
review are: DC, tophi, aggregates (all aspects of the urate
burden), and erosions (component of structural damage). 
Development of US consensus-based definitions of gout
lesions is the first initiative towards achieving a higher degree
of homogeneity and comparability of results between studies
and in daily clinical practice. The first steps in evaluating the
reliability of the definitions show moderate-to-perfect relia-
bility in static images and somewhat lower results in patients,
indicating that a standardized scanning technique and a core
set of joints are needed. Existing studies indicate that such a
core set of joints may include 1st MTP joints and knees,
although ankles and some tendons also appear to be
frequently involved19,20. The next step is to validate the
definitions following all steps covered by the OMERACT
filter. Further studies are already planned that aim to: (1)
investigate whether aggregates is an elementary lesion in gout
(because of poor reliability in static images and when
assessing patients) by conducting a Web-exercise to identify
what is perceived as aggregates; (2) determine respon-
siveness of lesions during urate-lowering therapy in a multi-
center prospective study; and (3) determine the discriminative
ability of US gout lesions, in comparison to those of other
arthropathies, in a patient workshop. The development of a
scoring system with possible inclusion of synovitis, tenosyno-
vitis, and Doppler activity will be a future step to ensure US
as an outcome measure in clinical trials.
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Budapest, Hungary, May 7-11, 2014
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Part 3 will appear in the December issue.
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